When Topical Rx Therapies Are Not Enough...
Fast Itch Relief that Lasts

In 3 pivotal trials, adult patients with moderate-to-severe atopic dermatitis not adequately controlled with topical prescription treatments were randomized to DUPIXENT 300 mg Q2W or placebo. In Trial 3, concomitant TCS was used. An endpoint included the reduction in itch from baseline to Week 16 (all trials) and 52 (Trial 3), as defined by ≥4-point improvement in the Peak Pruritus numerical rating scale (NRS).1

Significant Itch Relief

18+ years
Significant itch reduction (Peak Pruritus NRS) at Week 2 and Week 16 with DUPIXENT in Trial 1 (secondary endpoint)1-3,a,b
Trial 1: Monotherapy at 16 Weeks
  • 36% of adult patients with DUPIXENT (n=225) achieved ≥4‑point reduction in Peak Pruritus NRS score vs 10% with placebo at Week 16 in Trial 2 (n=221; P<0.001)1-3

Adult patients experienced a ≥4-point reduction in itch after the first dose as measured at Week 2 (≈9% vs ≈3%)1,2

  1. Subjects who received rescue treatment or with missing data were considered nonresponders.
  2. Full Analysis Set (FAS) includes all subjects randomized.

Sustained itch relief

18+ years

Sustained itch reduction (Peak Pruritus NRS) at 1 year with DUPIXENT + TCS in Trial 3 (secondary endpoint)2,4,a-c

Trial 3: Concomitant Therapy With TCS
Long-term itch reduction up to 52 weeks2

In a post hoc analysis of 3 pooled trials in adults
DUPIXENT monotherapy and DUPIXENT + TCS demonstrated consistent itch reduction across all tested racial groups vs placebo and placebo + TCS (black/African American, Asian, and white)5

  • Definitive conclusions cannot be made as this analysis was performed on only 16-week data, did not directly compare dose regimens, and only a small number of black/African American patients were available for analysis.
  1. Subjects who received rescue treatment or with missing data were considered nonresponders.
  2. FAS includes all subjects randomized.
  3. In Trial 3, as needed, subjects received topical calcineurin inhibitors for problem areas only, such as the face, neck, and intertriginous and genital areas.
  4. Week 52 data were limited to patients completing 52 weeks as of the cutoff date.

Pruritus NRS assesses the average itch intensity over the previous 24 hours6

A patient-reported measure that uses a 0- to 10-point scale, with which patients are asked6:


"On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?"

None
The Worst
Imaginable

A reduction of at least 4 points in pruritus NRS from baseline is a clinically meaningful change.1

EASI, Eczema Area and Severity Index; NRS, numerical rating scale.

Dosing and Administration Thinking about prescribing
DUPIXENT? Find the information you
need to get started.
Start Now
Connect With a Rep Have questions about DUPIXENT? Get
answers from a representative.
Request a Visit
DUPIXENT MyWay Get access support and information
about benefits investigations,
prior authorizations, and Medical
Necessity and appeal letters.
Explore Access Resources
References:
  1. DUPIXENT Prescribing Information.
  2. Data on file, Regeneron Pharmaceuticals, Inc.
  3. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  4. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomized, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  5. Alexis AF, Rendon M, Silverberg JI, et al. Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. J Drugs Dermatol. 2019;18(8):804-813.
  6. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-507.